OTTAWA, Ontario, Sept. 8, 2017 /Weed Wire/ – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug discovery, today announced that its Vice President of Business Development, Mr. Bob Bechard, is scheduled to attend the 10th Annual International Partnering Conference, BioPharm America, September 26-27 at the Sheraton Boston Hotel.
BioPharm America is one of the premiere BioPartnering events providing access to more than 500 companies and 800 delegates from all over the world, giving Tetra an excellent opportunity to showcase our robust product pipeline that is chasing multi-billion-dollar markets, including cancer pain, neuropathic pain, chemo induced vomiting and nausea, as well as eye pain and chronic pain. We will be holding one-on-one partnering meetings to carefully identify future partners for our innovative pipeline.
“Events like BioPharm America enable us to meet 100s of companies and delegates in a very short period of time allowing us to cost-effectively spread the word on the enormous potential of our business model,” said Bernard Fortier, CEO of Tetra Bio-Pharma. “The goal of these conferences is to start a dialogue with potential partners leading to strategic partnerships and bring in non-dilutive funding through up front and milestone payments, contributions to our research and development costs, and royalties. We are most excited in the future potential of our business strategy as we build Tetra into a global leader in cannabinoid-based drug discovery.”
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a clinical program aimed at bringing novel drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries that are engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.
Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
FOR FURTHER INFORMATION PLEASE CONTACT:
Tetra Bio-Pharma Inc.
Vice President, IR & Corporate Communications
(514) 360-8040 Ext. 203